Fosravuconazole L-lysine ethanolate 是一种口服广谱抗真菌剂，是Ravuconazole 的前药，可研究念珠菌病，灰指甲病和寄生虫病。

FosravuconazoleL-lysine ethanolate is a broad-spectrum antifungal agent. In Japan, it is approved for the treatment of onychomycosis, a fungal infection of the nail. It is a prodrug that is converted into ravuconazole.

Fosravuconazole has potent in vitro antifungal activity against a wide range of fungal species such as Candida, Aspergillus, and Trichophyton species[1].

Fosravuconazole (E-1224; 10-50 mg/kg; oral administration; daily; for 20 days) treatment suppresses the parasitemia and prevents death in mice infected with the T. cruzi Y strain[2].

914361-45-8

C31H40F2N7O8PS

739.73

E-1224 L-lysine ethanolate;BMS-379224 L-lysine ethanolate

DMSO:48mg/mL (64.89mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years